Cecilia Yeung, MD

Assistant Member
Clinical Research Division
Acting Assistant Professor
Univeristy of Washington


2001-2005 MD; Penn State College of Medicine, Hershey, PA
2005-2009 Anatomic and Clinical Pathology Residency; University of California Davis Medical Center, Sacramento, CA
2009-2010 Hematopathology Fellowship; Washington University, St. Louis, MO
2010-2011 Molecular Genetics Pathology Fellowship; Washington University, St. Louis, MO

Research Focus:

Dr. Yeung’s primary research interest is in molecular profiling of Myelodysplastic Syndromes. She believes molecular subgrouping of MDS patients through the use of genomic array, massive parallel sequencing, gene expression, as well as protein chemistry work will help identify more effective therapeutic options.

Her secondary interest is in transplant pathology. She and has several research projects examining infectious diseases seen in lungs of hematopoietic cell transplant patients and identifying specific T cell clones in the gut and skin from patients with graft versus host disease.

Clinical Expertise:

  • Hematopathology with particular interest in Myelodysplastic syndromes
  • Molecular Pathology with particular interest in chromosomal genomic microarray testing, and targeted gene capture next-generation sequencing.
  • Transplant pathology with particular interest in skin graft versus host disease and lung infections detectable by bronchoalveolar lavage.

Current Studies:

In relation to MDS:

1. HCT myeloma patients with acquired 20q deletions.

2. Post-HCT patients who develop subsequent hematopoietic disease from their donor cells: A multicenter collaborative study.

3. Mir Let-7b/EZH2/KDM2B pathway in MDS: A collaborative project with Drs. Marcondes (FHCRC) and Deeg (FHCRC). Please refer to Dr. Marcondes’s page for more information.

4. Chromosomal microarrays (CMA) in the analysis of MDS patients. Identifying specific morphologic or immunophenotypic patterns associated with abnormalities seen by CMA.

5. Collaborative study to examine gene expression patterns in response to specific therapies and to illicit specific molecular signatures which may infer responsiveness to the treatment, indicate impending severe toxicity, or can predict relapse.

In relation to transplant pathology:

1. T cell clonality in graft versus host disease. Preliminary spectral typing studies have identified recurrent T cell oligoclones in GVHD. A prevailing problem in early management of HCT patients is the inability before day 20 to differentiate drug effect versus early GVHD in skin and gut biopsies. After day 20, features of GVHD are still non-specific and can sometimes be difficult to distinguish from drug reaction, infections, and specific to the skin other inflammatory dermatoses.

2. HHV6 detection and its relationship to GVHD. HHV6 is highly prevalent in our population. Although most healthy people have latent forms that do not cause significant problems, HCT patients are a risk of reactivation and rarely patient’s develop fatal HHV6 encephalitis. Historically, HHV6 has been difficult to study in pathology tissues due to lack of a robust immunohistochemistry assay. However, more recently molecular testing can reliably detect HHV6 and we are utilizing these molecular methods in our research

3. Detection of biomarkers in the serum of patients with GVHD which indicate vascular damage.

Cecilia Yeung, MD

Contact Information

(206) 288-7104
(206) 288-1345
Additional contact

Mail Stop: G7-910